Saved in:
| Main Author: | |
|---|---|
| Format: | Recurso digital |
| Language: | English |
| Published: |
Zenodo
2023
|
| Subjects: | |
| Online Access: | https://doi.org/10.5281/zenodo.15814963 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Table of Contents:
- <p><strong>Background:</strong> The emergence of the global COVID-19 pandemic has highlighted the importance <br>of personalized healthcare approaches to meet individual patients’ unique needs. Personalized <br>medicine seeks to customize medical treatments based on individual characteristics like <br>genetics, biomarkers, and clinical data. </p> <p><br><strong>Objective:</strong> The primary objective of this study is to explore biomarkers that demonstrate <br>prognostic significance in the context of COVID-19. Identifying these biomarkers is expected <br>to significantly contribute to the augmentation of personalized treatment strategies tailored to <br>individuals exhibiting severe manifestations of COVID-19. </p> <p> <br><strong>Methods: </strong>This study employed a systematic literature review methodology that adhered to <br>established guidelines, to ensure a thorough and methodologically sound approach. A <br>systematic search strategy was devised for the PubMed database, encompassing carefully <br>chosen search terms that captured vital concepts pertaining to COVID-19 biomarkers, <br>personalized medicine, diagnosis, prognosis, and treatment strategies. The search strategy was <br>designed to identify relevant studies that met the research objectives. This study adhered to the <br>guidelines provided by PRISMA (Preferred Reporting Items for Systematic Reviews and Meta<br>Analyses), to ensure transparency in the review process,. </p> <p><br><strong>Results: </strong>The results section of this study encompassed a compilation of 40 relevant studies. <br>Within these studies, several biomarkers were identified that hold potential as indicators for <br>COVID-19 disease progression and the development of effective personalized therapeutic <br>strategies. These biomarkers include ACE2 tissue expression, cytokine storm syndrome, <br>lymphopenia, CD16+ monocytes, innate lymphoid cells, vitamin D deficiency, and the <br>haplotype Vindija 33.19 Neanderthals. </p> <p><br><strong>Conclusion: </strong>By recognizing biomarkers, healthcare professionals can enhance diagnostic <br>accuracy, prognostic assessment, and personalized treatment strategies for individuals affected <br>by COVID-19. Further research and validation of these biomarkers are warranted to advance <br>our understanding and improve patient outcomes in the era of personalized medicine. <br>Keywords: COVID-19, biomarkers, personalized medicine, advanced prognostic methods, <br>immunopathogenesis, immunotherapies. </p>